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Abstract. Noninfectious pulmonary complications of hematopoietic stem cell transplant are currently more prevalent than
infectious complications. Unfortunately, the pathophysiology basis is not completely understood. However, there is a string
association with graft-versus-host disease for many of them. Therefore, an important component of their pathophysiology is
likely an allo-immune response. There is much research that needs to be conducted to improve the less than optimal outcomes
for these disorders.
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1. Introduction
Non-infectious pulmonary complications of
hematopoietic stem cell transplant (HSCT) are poorly
understood. The names and classifications of these
disorders have evolved over time in the literature,
making them sometimes difficult to grasp. This article
aims to help bring clarity to the more common of these
disorders, with the exception of idiopathic pneumonia
syndrome (IPS), which will be discussed in a separate
article.
Pulmonary complications of HSCT are common,
affecting 5–25% of patients and are an important cause
of non-relapse mortality [1–5]. They remain an elusive
challenge for the transplant, pulmonary and critical
care communities. Outcomes for HSCT patients who
develop respiratory failure are much worse than those
of the general pediatric population as well as those
of non-transplant oncology patients. However, out-
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comes have demonstrated improvement over the last
two decades with the most recent studies reporting sur-
vival rates to pediatric intensive care unit discharge as
high as 40–58% [6–9] compared to an 88% mortality
rate reported in 1995 [10]. It is unclear if these improve-
ments are related to advancements in critical care
management, selection of more suitable candidates for
intensive care unit care or advancements in transplant
medicine, or some combination [11, 12]. An impor-
tant aspect is the shift from infectious complications
being the most prominent pulmonary complication
(prior to the 1990s) to the current decade in which non-
infectious complications have become more frequent
[13, 14].
Non-infectious pulmonary complications are often
classified as early and late onset. The timing of their
occurrence can help develop the differential diagno-
sis (Fig. 1). Complications more typically observed
in the first 100 days after transplant include dif-
fuse alveolar hemorrhage (DAH), peri-engraftment
respiratory distress syndrome (PERDS), also known
as engraftment syndrome, and pulmonary cytolytic
thrombi (PCT) [15]. Bronchiolitis obliterans or bron-
chiolitis obliterans syndrome (BOS), bronchiolitis
2146-4618/14/$27.50 © 2014 – IOS Press and the authors. All rights reserved
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Fig. 1. Approximate time of onset of non-infectious pulmonary complications following hematopoietic stem cell transplant. BO = Bronchiolitis
obliterans; BOOP = Bronchiolitis obliterans organizing pneumonia; DAH = Diffuse alveolar hemorrhage; DPTS = Delayed pulmonary toxicity
syndrome; IPS = Idiopathic pneumonia syndrome; PERDS = Peri-engraftment respiratory distress syndrome; PCT = Pulmonary cytolytic thrombi
(taken from ref. 2).
obliterans organizing pneumonia (BOOP), also known
as cryptogenic organizing pneumonia and pulmonary
veno-occlusive disease (PVOD) [3, 4, 15, 16], are
considered late complications. Less frequently, BOOP
may be seen in the first 100 days after transplant. As
survival of pediatric cancer has been extended for sev-
eral decades, we are beginning to gain more insight into
the late effects of treatment that may occur. HSCT sur-
vivors can develop both obstructive and restrictive lung
diseases up to several years after their initial treatment
[17].
The classification of IPS can be varied. A recent con-
sensus committee of the American Thoracic Society
defined IPS as having evidence of widespread alveolar
damage, which is not due to infection, cardiac disease,
renal failure or fluid overload [16]. Using this defi-
nition, many non-infectious pulmonary complications
from HSCT could fulfill the criteria. IPS can be seen
both early and late in the transplant course [15]. The
term IPS is often used interchangeably with intersti-
tial pneumonia or interstitial pneumonitis [18], it is
increasingly thought of as a spectrum disorder that
encompasses a myriad of disorders such as intersti-
tial pneumonitis, BOS, BOOP, DAH, PERDS, delayed
pulmonary toxicity syndrome and non-cardiogenic
capillary leak syndrome [18, 19]. At other times, only
a few disorders are lumped under its umbrella such as
DAH and PERDS [16] and early in the literature it is
often discussed as though it is a single entity.
Another source of controversy in the classification
of transplant associated lung disease involves the con-
cept of graft versus host disease (GVHD). In the early
2000s, whether or not the lung could be affected by
GVHD was debated in the literature [20]. However,
this concept is more widely accepted in the recent
literature [21–23]. In fact, BOS, BOOP, DAH, lympho-
cytic interstitial pneumonia, lymphocytic bronchitis,
eosinophilic interstitial pneumonia and non-specific
interstitial pneumonia are all considered to be mani-
festations of GVHD of the lung by some authors [24].
2. Early non-infectious pulmonary
complications
2.1. DAH
Alveolar hemorrhage can be a result of pulmonary
infections in HSCT patients; however the term DAH is
used to describe a non-infectious pulmonary complica-
tion in HSCT patients. Alveolar hemorrhage may occur
in patients other than HSCT recipients as a result of var-
ious disease processes (i.e. rheumatological diseases
such as systemic vasculitides), pharmacological agents
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(i.e. amiodarone) and infectious agents. However, no
clear pathophysiological mechanism has been sug-
gested to explain DAH in HSCT patients. Pulmonary
vascular injury, thrombotic microangiopathy forma-
tion [25] and inflammatory damage [26] have been
suggested as potential causes for DAH. Currently used
diagnostic criteria for DAH are 1) the presence of radi-
ological or clinical evidence of widespread alveolar
damage, for example multilobar, bilateral, interstitial
or alveolar infiltrates that are usually located centrally
in middle and lower zones of lung in chest radiographs
[27] or hypoxia with increased alveolar-arterial oxygen
gradient, 2) the absence of infectious causes for alve-
olar hemorrhage, 3) progressively increasing bloody
return of bronchoalveolar lavage fluid from three sep-
arate subsegmental bronchi, the presence of 20% or
more hemosiderin-laden macrophages or the presence
of blood in at least 30% of the alveolar surface [28, 29].
DAH usually develops within 30 days post-HSCT
[28] and coincides with the engraftment of stem cells.
Signs of respiratory distress and fever are common
clinical findings whereas hemoptysis is an uncommon
symptom of DAH in HSCT patients. The incidence
of DAH is reported to be about 5% in pediatric
HSCT patients [30] and significantly higher in pedi-
atric HSCT patients with an underlying diagnosis
of mucopolysaccharide storage disorders [31, 32].
Although initially DAH was thought to be more com-
mon in allogeneic HSCT patients than autologous,
Afessa et al. [28] did not find any difference in DAH
incidence between allogeneic and autologous HSCT
patients when they combined all previously reported
DAH cases.
Surprisingly, neither low platelet count nor pro-
longed prothrombin time were associated with DAH
and correcting low platelet counts did not seem to
improve DAH in one report [29]. Mortality due to DAH
in pediatric HSCT patients remains high ranging from
57% [30] to 83% [33]. High dose corticosteroids have
been reported to decrease mortality and the need for
mechanical ventilation [34]. Despite a lack of concrete
evidence for their efficacy, corticosteroids are consid-
ered standard of care for DAH within the transplant
community. However, more recent studies have not
confirmed those findings [35]. Recombinant human
factor VIIa has been used in DAH treatment to control
bleeding [36], but was not found to improve survival
[37]. Similarly, the addition of aminocaproic acid,
an antifibrinolytic agent, to a high dose methylpred-
nisolone regimen was reported to be promising in a
retrospective study among adult HSCT patients [38].
There is also a reported case of successful use of extra-
corporeal membrane oxygenation in a pediatric HSCT
patient with DAH [39].
2.2. PERDS
PERDS is defined as a constellation of symp-
toms including; fever, diffuse erythematous skin
rash, weight gain, non-cardiac pulmonary edema,
and pulmonary infiltrates on radiographs, hypoxia,
hepatic dysfunction, renal insufficiency and transient
encephalopathy [40]. However, there is no consen-
sus about clear diagnostic criteria of PERDS [41, 42].
The incidence of PERDS is reported to range from
17% to 48% [42–45]; however, investigators have used
different criteria for PERDS rendering it difficult to
ascertain the true incidence. As its name suggests,
PERDS occurs around the time of neutrophil engraft-
ment. In one study, PERDS occurred at median of
14 days (range 8–27 days) post-HSCT with a median
time to neutrophil recovery >500/mm3 being 16 days
(range 13–26 days) [45]. PERDS is believed to be
due to capillary leak resulting from complex interac-
tions between the host’s existing immune system and
transplanted stem cells. This results in the release of
pro-inflammatory cytokines during engraftment and an
influx of neutrophils into the lungs and other organs.
PERDS can be found in both autologous and allogeneic
HSCT patients, but appears to occur more commonly in
autologous HSCT patients [45]. Supportive care with
supplemental oxygen, mechanical ventilation, close
attention to maintaining a stable fluid balance and pro-
phylactic antibiotics are commonly used. PERDS has
been found to respond to corticosteroids within 3 days
of administration [42, 46]. Survival from PERDS is
relatively good, being >90% in recent reports [45].
Overall survival rates after HSCT did not seem to be
different in HSCT patients with or without occurrence
of PERDS [42, 45].
2.3. PCT
PCT is an uncommon and recently recognized
noninfectious pulmonary complication. It was first
described in 2000 [47] in a small case series with
13 HSCT recipients. Twelve of those patients were
younger than 18 yr of age with a median age of 11.9 yr.
Nine of those 13 patients survived in this case series
[47]. All patients had fever at a median of 72 days
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(range, 8–343 days) post-HSCT along with cough in
two patients. Pulmonary nodules were described on
chest computerized tomography (CT). Pathological
examination of those nodules revealed a unique
pattern of necrotic, basophilic thromboemboli with
amorphous material suggestive of cellular breakdown
products. Immunohistochemical staining revealed
entrapped leukocytes and disrupted endothelium.
Those leukocytes were later identified as monocytes
[48].
Infarcted lung parenchyma adjacent to PCTs is fre-
quently noted in biopsies likely secondary to entrapped
debris in blood vessels. Chest CT usually reveals
bilateral small nodules (few millimeters to 1.2 cm) typ-
ically in the peripheral, subpleural and basilar regions.
Final diagnosis and differentiation of PCT from other
pulmonary nodules in HSCT patients requires patho-
logical examination. Acute and chronic GVHD is more
commonly observed in patients who developed PCT
as compared to those without PCT [49]. Interestingly,
leukemia patients who receive an HSCT and develop
PCT are at lower risk of relapse [49]. PCT is reported
to be responsive to intravenous methylprednisolone
and cyclosporine within 1-2 wk with clinical improve-
ment and near complete radiological resolution of
pulmonary nodules [47, 50].
3. Non-infectious pulmonary complications
after 100 days
3.1. BOS and chronic GVHD of the lung
The occurrence of chronic GVHD of the lung has
been a debatable entity [18]. It is now believed to exist,
although it is still not well understood. In 2005, an NIH
consensus paper defined criteria for the diagnosis of
chronic GVHD of the lung. Chronic GVHD of the lung
was defined as either 1) biopsy proven BOS or 2) BOS
diagnosed by typical pulmonary function test (PFT)
and radiologic findings associated with chronic GVHD
at another site. Typical PFT findings include forced
expiratory volume in 1 sec (FEV1)/forced vital capac-
ity (FVC) ratio <0.7 and an FEV1 <75% predicted.
CT findings include air trapping and small airway
thickening or bronchiectasis. High-resolution CT find-
ings with inspiratory and expiratory cuts demonstrate
a residual volume >120% predicted [21].
Despite the consensus statement from the NIH,
there is discussion in the literature regarding chronic
Table 1
Risk factors for bronchiolitis obliterans syndrome
Risk factors References
Probable
Older age of donor 70, 75, 77
Obstructive lung disease prior to
hematopoietic stem cell transplant
70, 75
Viral infection, particularly within the first
100 days following transplant
70, 75
Possible
Busulfan-based conditioning regimen 72, 74
Human leukocyte antigen matching 92
Hypogammaglobulinemia 76, 92
Methotrexate prophylaxis against graft
versus host disease
92
Chronic myeloid leukemia 72
Female donor to male donor 60
Interval from leukemia diagnosis to
hematopoietic stem cell transplant of
greater than 14 mo
60
GVHD of the lung being manifest as entities other
than just BOS. In a study by Xu et al. [23], lung
biopsies in patients with respiratory symptoms and
chronic GVHD had significant variation in histology.
The appearance of biopsy specimens included acute
lung injury, organizing pneumonia and chronic inter-
stitial pneumonia. BOS developed in the group whose
biopsy specimen revealed chronic interstitial pneumo-
nia [23]. Other late-onset pulmonary complications
hypothesized to be possible alternative manifesta-
tions of chronic GVHD include BOOP, IPS, DAH,
lymphocytic bronchitis, eosinophilic pneumonia and
non-specific interstitial pneumonia [3, 24]. Despite the
discussion in the literature, chronic GVHD of the lung
being manifested as anything other than BOS is not
widely accepted within the transplant community.
BOS is a fibrotic disorder of the terminal and res-
piratory bronchioles that leads to progressive airflow
obstruction with a notable absence of parenchymal
infiltrates on chest radiograph and poor response to
therapy [51–54]. It was first described in 1978 [55]
when lymphocytic bronchitis was reported in 10% of
HSCT lung biopsies. While it has been reported to
be the most common, late pulmonary complication of
HSCT [56], the incidence in the literature varies rang-
ing from 2–26% likely due to the lack of a consistent
definition [56–59]. In one review of 2152 allogeneic
HSCT recipients, BOS was reported to occur in 8.3%
of the cohort [15]. Another investigation of 1131
allogeneic HSCT patients noted a general incidence
of BOS of 26% with this number increasing to 32%
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in the presence of chronic GVHD [56]. In contrast, a
review of the International Bone Marrow Transplan-
tation Registry noted an incidence of only 1.7% at 2
yr after transplantation in matched sibling transplants
[60].
Risk factors for the development of chronic GVHD
of the lung include peripheral blood stem cell source
[61], busulfan use during conditioning, hypogamma-
globulinemia, an unrelated donor source, and the use of
methotrexate for GVHD prophylaxis. Alam et al. [61]
reported that the risk of developing chronic GVHD of
the lung was 40% at 2 yr for patients who received
matched unrelated donor transplants with peripheral
blood as the stem cell source. In comparison, patients
who received matched related donor transplants with
bone marrow as the stem cell source only had an 11.9%
risk of developing chronic GVHD of the lung.
Chronic GVHD at any site has been described
as a significant risk factor for the development of
late-onset pulmonary complications in several studies.
Eikenberry et al. [1] reviewed charts from 363 chil-
dren who received an allogeneic stem cell transplant
over a 5 yr period. Ninety (25%) of these children
developed pulmonary complications. He found that
patients with grade III-IV GVHD had two times the
risk of developing pulmonary complication [1]. Nishio
et al. [3] found an association between chronic GVHD
and development of late onset non-infectious pul-
monary complications in a cohort of 97 allogeneic
pediatric stem cell transplant patients. Several others
have reported similar findings [4, 63, 64].
Numerous risk factors for BOS have been explored
(Table 1). One consistent risk factor is allogeneic trans-
plant; it typically does not develop post autologous
transplant with only a few cases reported [65–67]. It is
exceedingly rare post umbilical cord blood transplant
with only a few biopsy proven case reports [68, 69].
The most important risk factor identified for BOS is
GVHD at any site, especially if it is chronic and pro-
gressing [70–75]. One study found the prevalence of
BOS to be 6% in allogeneic transplants with chronic
GVHD [76]. In another report, 81% of all BOS patients
were found to have GVHD at another site [77].
The pathophysiology of BOS is not completely
elucidated, but there is accumulating evidence that
suggests a T-cell mediated recognition of alloantigens
in lung tissue is responsible for the underlying pro-
cess. One piece of evidence supporting this theory is a
decreased frequency of BOS in patients who receive T-
cell depleted grafts [78]. The lung epithelium is likely
the site of immune mediated-injury induced by donor
cytotoxic T cells in GVHD [76]. The lymphocytes
infiltrate the blood vessels and small airways lead-
ing to epithelial cell necrosis. This necrosis releases
inflammatory mediators causing migration of fibrob-
lasts, smooth muscle proliferation, and finally collagen
and fibrous deposition in the lumen of the airways [79].
There are several proposed mechanisms for the
development of BOS. The most important mechanisms
is likely the alloreactive immune process described
above where the donor T cell lymphocytes target
the epithelial cells of the bronchioles leading to the
inflammatory reaction observed in BOS. As a result,
some suggest that BOS is simply a continuum of
GVHD [80]. A number of potential precipitants of
the lung injury observed in BOS have been identi-
fied. The conditioning regimen has been suggested
due to the higher incidence of BOS in those treated
with busulfan-based conditioning regimens [72, 74]
and the lower incidence in those receiving a non-
myeloablative HSCT [81]. There is also evidence that
the development of BOS is related to infections with
risk factors of hypogammaglobulinemia, associated
viral infection, and impaired mucocilliary clearance
noted in chronic GVHD leading to recurrent bronchial
infections [82]. Another association with GVHD is the
related esophagitis that may result in recurrent aspi-
ration causing lung irritation and inflammation. This
association has been linked with BOS following lung
transplantation [83–85]. Additionally, BOS may be the
end result following acute lung injury in the HSCT
recipient [86]. In sum, it is likely that BOS is the
result of a multitude of factors, perhaps in combination,
including chemotherapy, infection, and an alloreactive
immune reaction.
In an effort to establish a formal definition for BOS,
the NIH released a consensus statement in 2005 with
a proposed amendment in 2009 (Table 2). As BOS is
traditionally a clinical diagnosis, there have been sug-
gested diagnostic criteria including: allogeneic HSCT,
chronic GVHD, insidious onset of respiratory symp-
toms (dyspnea, cough, wheezing) greater than 100 days
following transplant, exclusion of an infectious pro-
cess, PFTs demonstrating new airflow obstruction, a
normal chest radiograph, and a high resolution chest
CT with areas of air trapping, hyperinflation, and/or
bronchial dilation with no parenchymal involvement
[87].
Clinically, the majority (80%) of patients with BOS
present between 6 and 12 mo following HSCT [76, 88,
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Table 2
Consensus definition of bronchiolitis obliterans syndrome
National Institutes of Health consensus definition 2005 [44] Proposed National Institutes of Health amended 2009 [126]
No active infection Same
Another chronic graft versus host disease manifestation Same
Forced expiratory volume in 1 sec <75% predicted Forced expiratory volume in 1 sec <75% predicted or
decline >10%
Forced expiratory volume in 1 sec/forced expiratory vital
capacity <0.70
Forced expiratory volume in 1 sec/forced expiratory vital
capacity <0.7 or residual volume or residual volume/total
lung capacity >120% and computerized tomography
findings of air trapping or bronchiectasis
Residual volume >120%
Computerized tomography findings of air trapping or
bronchiectasis
89]. Initial symptoms may include a dry cough, wheez-
ing, sinusitis, and dyspnea, particularly on exertion [19,
90]. On physical exam, the patient may exhibit signs of
hyperinflation, decreased breath sounds and evidence
of GVHD. While patients are typically afebrile with-
out evidence of active infection, patients may have a
history of recurrent respiratory tract infections and air-
way colonization with pseudomonas, staphylococcus
and aspergillus. Several diagnostic studies, including
radiologic, tissue biopsy and PFT can be used to sup-
port the diagnosis of BOS (Table 3). For example, the
findings of fibrin deposition obliterating the lumen of
the bronchioles on lung biopsy can aid in the diag-
nosis. Further lung biopsy discoveries and additional
study findings are summarized in Table 3.
Serial PFTs may be used to aid in making an earlier
diagnosis of obstructive lung disease. Chien et al. [91]
found that abnormalities seen on pre transplant PFTs
were associated with an increased risk of developing
pulmonary complications after transplant. Their group
recommends that all patients undergo PFTs prior to
HSCT both as a screening tool for future pulmonary
complications as well as to have baseline PFTs in
the event the patients develop respiratory symptoms
after transplant. Patients who have abnormalities seen
on pre-transplant PFTs would be followed with serial
PFTs even if they are asymptomatic. This has become
standard practice at many pediatric transplant centers.
Treatment for BOS is based on small, uncontrolled
trials and expert opinion. Many of the therapies used
are similar to GVHD. First line therapy has remained
systemic corticosteroids with an initial burst and a pro-
longed taper over 6–12 mo [15, 77, 92–94]. Inhaled
corticosteroids have exhibited only minor success [9].
Immunosuppressive therapy has also been traditionally
accomplished with cyclosporine or tacrolimus [15, 73,
77], but azathioprine has been used successfully [73,
77, 92]. Second line treatments such as azithromycin
[71] and tumor necrosis factor-alpha inhibitors [95, 96]
have had some success in small studies. There have
been small studies that suggest the combined use of
fluticasone, azithromycin and montelukast, known as
Table 3
Summary of diagnostic study findings in bronchiolitis obliterans syndrome
Studies Findings
Chest radiograph Initially normal, but then can progress to bronchiectasis, with dilated thickened bronchi
Chest computerized tomography Hyperinflation, air trapping, bronchiectasis, areas of hypoattenuation with obstruction, ground
glass appearance of patent airways
Bronchoscopy Little value in the diagnosis except to exclude infection. Bronchial alveolar lavage may
demonstrate higher levels of tumor necrosis factor-alpha [126]
Pulmonary function tests Airflow obstruction with decreased forced expiratory volume in 1 sec and forced expiratory
volume in 1 sec/forced expiratory vital capacity, a 20% decrease from baseline in forced
expiratory volume in 1 sec, a lack of improvement in forced expiratory volume in 1 sec with
a bronchodilator [54, 88, 92]
Lung biopsy Bronchiolitis of the small airways, fibrin deposition obliterating the lumen of the bronchioles;
polymophonuclear leukocytes and mononuclear cells are present early. As the bronchiolitis
obliterans syndrome progresses, there is variable degree of intraluminal and peribronchiolar
fibrosis [127, 128]. This fibrosis leads to scaring creating new and worsening airflow
obstruction
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FAM, can be used to minimize corticosteroid expo-
sure without compromising lung function based on
PFT results [97]. Extracorporeal photopheresis has
demonstrated mixed results [98, 99], while intravenous
immunoglobulin has been found to not be effective
[100].
The reported mortality rate is highly variable rang-
ing from 14–100% with a median of 65% [19, 65,
73, 76, 88, 89, 101, 102]. It is well demonstrated
to be a progressive disease with irreversible airflow
obstruction. At this time, stabilization of the process
and prevention of further deterioration in the FEV1 is
the best outcome described. The 2 yr survival rate is
reported to be approximately 44% while the 5 yr sur-
vival rate drops to 13% [56, 70, 77, 88, 92]. Concerning
prognostic signs include rapid deterioration of FEV1,
underlying active disease at the time of transplant, dis-
ease relapse, viral infections, the early development of
BOS and a lack of response to the initial treatment for
BOS [56, 70, 77, 92].
3.2. BOOP
BOOP, also known as cryptogenic organizing pneu-
monia, was first described in 1985 [103]. It is a
non-infectious disorder that involves the bronchioles,
alveolar ducts, and the alveoli. The lumens of the bron-
chioles and the distal air spaces become filled with
granulation tissue consisting of both fibroblasts and
connective tissue. There is inflammation, but no fibro-
sis of the bronchiolar walls [104]. The incidence is
reported to be between 1% and 2% [105, 106]. Risk
factors for BOOP are similar to BOS in that the major-
ity of cases occur post-allogeneic transplant and in
patients with GVHD [105, 106]. A decreased inci-
dence of BOOP following T-cell depleted HSCT has
also been noted [78]. Human leukocyte antigen dis-
parity and female gender have been suggested to be
associated with an increased incidence of BOOP [59].
The pathophysiology of BOOP is poorly under-
stood. There is some consideration that its development
is secondary to an alloimmunologic reaction. Animal
studies suggest that there is a role for T-cell and Th1-
derived cytokines such as tumor necrosis factor-alpha
leading to the inflammatory process observed [107].
Though rare, BOOP has been described in children
after autologous HSCT. Therefore, an alloimmuno-
logic reaction may not be the only mechanism involved
[108]. Regardless of the precipitating insult, it appears
that BOOP is secondary to alveolar epithelial injury
[109, 110]. This injury leads to leaking of plasma
proteins into the alveolar lumen causing fibroblast
recruitment and fibrin formation.
Clinically, patients present acutely with fever,
cough, and dyspnea within the first 2–6 mo post-HSCT
[111, 112]. The median day of occurrence, while vari-
able, has been found to be 108 days post-transplant
[105]. On exam, rales and crackles may be detected.
Most patients have bilateral airspace disease with con-
solidated infiltrates on chest CT. Laboratory work may
reveal a moderate leukocytosis with neutrophilia and
an elevated C-reactive protein level. Biopsy is usually
required to establish the diagnosis. Additional diagnos-
tic studies may aid in the diagnosis of BOOP (Table 4).
Also, important to recognize that BOS and BOOP
are two very different clinical entities (Table 5). The
mainstay of treatment for BOOP remains systemic cor-
ticosteroids. Generally, patients are placed on higher
treatment doses for several months followed by a pro-
longed gradual taper, which may take up to a year.
However, this prolonged steroid taper has not been
found to create a significant difference in outcome or
survival [105].
The outcome with BOOP from all causes is gener-
ally good particularly if there is a quick response to
the steroid therapy. Survival rates have been reported
to be between 50–70% [105, 106]. However, BOOP
that follows HSCT is not as well defined and likely has
a higher mortality than idiopathic BOOP [113, 114].
In one report of BOOP following HSCT, 57% of cases
resolved, 21% remained stable, and 22% progressed
[105].
3.3. PVOD and pulmonary hypertension
PVOD is a rare complication of HSCT and is a
form of pulmonary hypertension. Pulmonary hyper-
tension is defined as an increase in pulmonary vascular
resistance with a resulting increase in right ventricular
pressure >50% of systemic pressures or >25 mmHg
[115, 116].
Pulmonary hypertension has been described in both
oncology and HSCT patients, but is incompletely
understood. Some cases of pulmonary hypertension
reported in the literature have been attributed to PVOD
[117], a type of pulmonary arterial hypertension, while
others were likely due to chronic lung disease [14].
The incidence of pulmonary hypertension in the HSCT
population is unknown given the lack of prospective
studies screening for the disorder. However, from avail-
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Table 4
Summary of study findings in bronchiolitis obliterans organizing pneumonia
Studies Findings
Chest imaging Peripheral airspace consolidation with ground-glass and nodular opacities [111, 112]; consolidation is
predominantly subpleural with peribronchovascular distribution in 60% of patients [129]. Bronchiolitis
obliterans organizing pneumonia following hematopoietic stem cell transplantation has more ground
glass appearance, less areas of consolidation and more frequent pulmonary nodules than
immunocompetent patients [129]
Bronchoscopy Bronchial alveolar lavage demonstrates a lymphocytosis and a decreased CD4/CD8 ratio
Pulmonary function tests There is no airflow obstruction noted. A restriction defect can be found with forced expiratory vital
capacity <80% and/or forced expiratory volume in 1 sec/forced expiratory vital capacity ≥80%
Lung biopsy Biopsy is usually required to establish the diagnosis [130]. Granulation tissue filling distal airways,
alveolar ducts and sacs, foamy macrophages in the alveoli, chronic interstitial inflammation, and
widening of the alveolar septa due to infiltration of mononuclear cells [131]
Table 5
Summary comparison of bronchiolitis obliterans syndrome and bronchiolitis obliterans organizing pneumonia
Characteristics Bronchiolitis obliterans syndrome Bronchiolitis obliterans organizing pneumonia
Incidence Highly variable; ranging from 2–10% 1-2%
Pathophysiology Lymphocyte infiltration of blood vessels and
small airways leads to epithelial cell necrosis
releasing inflammatory mediators causing
migration of fibroblasts, smooth muscle
proliferation and finally collagen and fibrous
deposition in the lumen of the airways
Secondary to alveolar epithelial injury leading to
leaking of plasma proteins into the alveolar lumen
causing fibroblast recruitment and fibrin formation
Major risk factors Allogeneic hematopoietic stem cell transplant,
chronic graft versus host disease
Allogeneic hematopoietic stem cell transplant, graft
versus host disease
Timing of onset Later; 6–12 mo post-hematopoietic stem cell
transplant
Earlier; 2–6 mo post- hematopoietic stem cell transplant
Clinical findings Insidious; cough, dyspnea on exertion, afebrile Acute; cough, dyspnea, fever, rales, crackles
Radiographic findings Hyperinflation, bronchiectasis, air trapping;
ground glass appearance in patent airways
Airspace consolidation with ground glass and
pulmonary nodules
Bronchoscopy findings Not useful Lymphocytosis, decreased CD4/CD8 ratio
Pulmonary function tests Obstructive findings Restrictive findings
Biopsy Bronchiolitis of small airways; fibrin deposition
obliterating the lumen of the bronchioles
Granulation tissue filling distal airways, alveolar ducts
and sacs, alveoli with foamy macrophages, chronic
interstitial inflammation
Therapy Systemic corticosteroids and
immunosuppressants
Systemic corticosteroids
Outcomes Poor prognosis; progressive disease Better prognosis; potentially reversible
able retrospective reports, the incidence varies from
2.4% to 28% [118]. This variability likely reflects dif-
ferences in the screening and diagnosis of pulmonary
hypertension, in the underlying disorder being treated
with HSCT, in the conditioning regimens and in the
subsequent complications from HSCT. The incidence
of PVOD in the general population is estimated at
0.1–0.2 cases per million [119]. The incidence of
PVOD as the cause of pulmonary hypertension in the
HSCT population is speculative given the limited avail-
able data [117].
Pulmonary hypertension has been described in var-
ious types of hemolytic anemias [118]. Therefore,
it is not surprising that it has been described in
HSCT patients with transplant associated - throm-
botic microangiopathy [115, 120], a microangiopathic
hemolytic anemia [90]. Pulmonary hypertension has
also been described in malignant infantile osteopetro-
sis patients undergoing HSCT [121]. In this case series,
five of 12 osteopetrosis patients developed significant
pulmonary hypertension, which was fatal in four of the
five cases. Fatal pulmonary hypertension has also been
described in pediatric patients undergoing HSCT for
hemophagocytic lymphohistiocytosis and idiopathic
myelofibrosis [122, 123]. Whether or not any of these
case reports represent PVOD is unclear, as differenti-
ating PVOD from other causes of pulmonary arterial
hypertension is difficult.
The pathophysiology of PVOD in HSCT patients
is speculated to involve endothelial cell damage [117,
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118]. Histologically, there are similarities between
PVOD and hepatic VOD. Therefore, important patho-
physiologic mechanisms in hepatic VOD such as
nitric oxide dysregulation and plasminogen activator
inhibitor-1 up regulation may play a similar impor-
tant role in PVOD. There is likely a role for a genetic
predisposition to PVOD as abnormalities in the bone
morphogenetic protein receptor type II have been
described in pulmonary hypertension [118] as well as
in PVOD [119].
The clinical presentation of PVOD and other forms
of pulmonary hypertension is nearly indistinguishable.
In the early stages, patients may be asymptomatic. As
the disease progresses, patients develop progressive
dyspnea, hypoxemia and signs of right heart failure
[116–119]. On physical exam, the patients may have
peripheral edema, hepatomegaly, jugular venous dis-
tention, a loud second heart sound and a holosystolic
murmur from tricuspid regurgitation [117, 118]. Club-
bing and pleural effusions are more frequent in PVOD
than other forms of pulmonary hypertension. Chest
radiographic findings in PVOD may demonstrate peri-
hilar pulmonary congestion and enlarged hilar vessels.
High-resolution CT may illustrate dilation of the pul-
monary arteries, interstitial pulmonary edema, diffuse
ground glass opacities, interlobular septal thickening
and mediastinal lymphadenopathy [117, 118].
Echocardiogram is most frequently used to eval-
uate for pulmonary hypertension due to its safety
profile. Echocardiographic findings may be normal
in early stages of pulmonary hypertension. There-
fore, if suspicion remains, serial echocardiograms
may need to be performed. Echocardiogram findings
of pulmonary hypertension include flattening of the
ventricular septum, right atrial dilatation and dilated
pulmonary arteries [118]. The echocardiogram can-
not differentiate between PVOD and other forms of
pulmonary hypertension. Other diagnostic modalities
to diagnose pulmonary hypertension include cardiac
magnetic resonance imaging, which may demonstrate
similar findings as the echocardiogram, but with better
definition [118].
Right heart catheterization is the gold standard for
diagnosing pulmonary hypertension. Pulmonary artery
pressures and cardiac output can be measured and pul-
monary vascular resistance can be calculated [118].
If pulmonary hypertension is detected, further testing
may be performed to determine whether or not it is
responsive to vasodilator therapy. Right heart catheter-
ization requires sedation and carries more risk than
echocardiography. Therefore, it is reserved for patients
in whom the diagnosis has been challenging or for those
who are not responding as expected to therapy [118].
In order to differentiate PVOD from other types
of pulmonary hypertension, lung biopsy was pre-
viously believed to be essential. However, it has
recently been suggested that putting together the
clinical picture with diagnostic testing may be suf-
ficient [116, 124]. PFT would be characterized by
a normal forced expiratory volume, functional vital
capacity, and total lung capacity, but reduced diffusing
capacity (carbon monoxide diffusing capacity) <50%
predicted [124]. Bronchoalveolar lavage may contain
evidence of occult hemorrhage with increased num-
bers of hemosiderin-laden macrophages [125]. CT will
demonstrate patchy ground glass opacities in 83%
of cases and thickening of interlobular septal lines
in 50% [116]. Mineo et al. [124] demonstrated that
the presence of two of three CT findings (i.e. ground
glass appearance, septal thickening and mediastinal
lymphadenopathy) identified PVOD with 95.5% sen-
sitivity and 89% specificity. Lung biopsy in these
patients carries a significant risk. If histology testing is
done, the typical appearance of PVOD is that of patchy
fibrous intimal proliferation involving the pulmonary
venules and small veins with a gradual reduction in
the vascular lumen to the eventual complete occlusion
of the vessel [124]. Treatment of PVOD is primar-
ily supportive care. Oxygen, anticoagulation, diuretics,
avoidance of tobacco and physiologic stress, and
immunizations to prevent lung infections are impor-
tant aspects of treatment [119]. Pulmonary vasodilators
used in other types of pulmonary hypertension may be
poorly tolerated in PVOD. The increased blood flow
caused by the vasodilating agent may cause an increase
in transcapillary hydrostatic pressure leading to the
development of pulmonary edema. While vasodilators
have been beneficial in some patients, fatal pulmonary
edema associated with pulmonary vasodilator therapy
has been described [117, 119]. If these medications are
implemented, patients should be observed closely for
signs and symptoms of worsening respiratory distress
as an inpatient.
Corticosteroids have been used to combat any
inflammatory component of the disease, but with-
out consistent results [117]. Other immunosuppressive
agents such as azathioprine and cyclophosphamide
have been tried with limited success [116, 119]. Lung
transplantation is currently the only curative option
[117, 119]. However, the time to transplant may be
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prohibitive with patients dying while awaiting trans-
plant [117]. Defibrotide and N-acetylcysteine, both
promising treatments for hepatic VOD, may be use-
ful in PVOD. However, given the small numbers of
PVOD patients, evaluation will be difficult [117].
In conclusion, pulmonary complications after HSCT
often present insidiously with similar presentations
such as increasing work of breathing and a new oxy-
gen requirement. In the early stages, they are often
difficult to differentiate. Typically, when these patients
arrive in the pediatric intensive care unit, it is difficult
to diagnose the specific etiology of respiratory failure.
However, increasing clinician’s knowledge and aware-
ness of the specific pulmonary complications of HSCT
could lead to earlier intervention and improve out-
comes for these fragile patients. Improving definitions
of these pulmonary complications will aid in our ability
to conduct well designed research trials for improving
diagnostic capabilities or studying novel therapies.
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